Cartesian Therapeutics, Inc.
RNAC
Peringkat dalam Saham
#18243
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
Harga Saham
$6.42
Kapitalisasi Pasar
$194.24M
Perubahan (1 hari)
5.59%
Perubahan (1 tahun)
862.09%
Negara
US
Perdagangan Cartesian Therapeutics, Inc. (RNAC)
Kategori
Healthcare
Riwayat pemecahan saham untuk Cartesian Therapeutics, Inc. (RNAC)
Saham Cartesian Therapeutics, Inc. (simbol: RNAC) telah mengalami total 0 kali pemecahan saham.
Pemecahan saham terbaru terjadi pada Oct 20, 2026.
Satu lembar saham RNAC yang dibeli sebelum Oct 20, 2026 sekarang setara dengan 0 lembar saham RNAC.
Pemecahan saham terbaru terjadi pada Oct 20, 2026.
Satu lembar saham RNAC yang dibeli sebelum Oct 20, 2026 sekarang setara dengan 0 lembar saham RNAC.
Daftar pemecahan saham
| Tahun | Pemecahan | Kelipatan | Kelipatan Kumulatif |
|---|---|---|---|
| Tidak cukup data untuk tanggal yang disediakan. | |||
Pemecahan saham untuk perusahaan sejenis atau pesaing
| Perusahaan | Jumlah pemecahan saham | Kelipatan Kumulatif | Negara |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
